Genmab Announces Approval of EPKINLYTM to Treat Relapsed or Refractory Large B-Cell Lymphoma

Genmab announced the approval of EPKINLYTM (epcoritamab) by the Japan Ministry of Health, Labour and Welfare, marking a significant advancement in the treatment of certain types of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in adult patients who have undergone two or more lines of systemic therapy.

Epcoritamab is a bispecific antibody of the IgG1 class, developed using Genmab's proprietary DuoBody® technology. This technology, specifically DuoBody-CD3, is engineered to selectively direct cytotoxic T cells to target specific cell types, triggering an immune response. 

EPKINLY is designed to bind to CD3 on T cells and CD20 on B cells. This unique dual binding capability enables EPKINLY to induce T-cell mediated killing of CD20+ cells, primarily B cells.

The approval of EPKINLY in Japan is based on the results from two open-label, multi-centre studies that were specifically designed to assess the safety and initial effectiveness of EPKINLY when administered as monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).

The approval of EPKINLY in Japan addresses a significant unmet medical need, offering a new therapeutic option for adult patients with R/R LBCL who have exhausted other treatment options. 

Despite advancements in LBCL treatment, the prognosis for patients with relapsed or refractory LBCL remains generally poor. EPKINLY's innovative mechanism of action and administration via subcutaneous injection provide hope for improved outcomes in this challenging medical condition.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!